|Number of samples:||24|
|Release date:||Feb 28 2017|
|Last update date:||Nov 28 2018|
|Diseases:||Breast Neoplasms, Neoplasms|
|Genes:||DNER, BRD2, BRD3, BRD4, BRDT, MCL1|
|Dataset link||Global transcriptome profiling of triple-negative breast cancer cell lines treated with small-molecules targeting Bromodomain and Extra Terminal (BET) proteins|
Global gene transcription profiling was performed in MDA-MB-157, MDA-MB-231 and MDA-MB-468 cell lines treated with DMSO, Thalidomide (1000 nmol/L), BETi-211 (1000 nmol/L) or BETd-246 (100 nmol/L) for 3 hours. Independent biological replicates (such as DMSO1 and DMSO2) were analyzed for each cell line under each condition. Both DMSO- and Thalidomide-treated samples were used as controls.